This series of bite-sized episodes contains important information you need to navigate the evolving world of Alzheimer’s disease (AD) research. Dr. Marc Agronin and Dr. Richard Isaacson discuss the recent advances in AD and provide practical approaches for prevention, diagnosis, and treatment.
The Role of Biomarkers in Alzheimer's Disease
The Role of Biomarkers in Alzheimer's Disease
Welcome to CME on ReachMD. This episode is part of our MinuteCME curriculum.
Prior to beginning the activity, please be sure to review the faculty and commercial support disclosure statements as well as the learning objectives.
This is CME on ReachMD, and I'm Dr. Marc Agronin. I'm here today with my colleague Dr. Richard Isaacson.
Dr. Isaacson, biomarkers are emerging as really hot topics in Alzheimer's disease right now. And I wanted to ask you, you know, what are these biomarkers? What role do they play in Alzheimer's disease? And let's talk a little bit about what patients need to pursue in order to get at the best diagnosis.
Sure. So I think most people may or may not be aware that Alzheimer's disease is actually characterized by a very specific set of neuropathological changes. We've known for a long time that the brain shrinks as we get older, and especially in certain areas related to Alzheimer's pathology. But much more specific than just shrinkage of the brain, but we also have biomarkers, AD-specific biomarkers that include amyloid, tau, as well as neurodegeneration.
And really where our field is going and where it really almost is today is the ability to assess these different types of amyloid ratios, different isoforms or different types of tau, as well as different markers of neurodegeneration. For example, neurofilament light, GFAP, there's a variety of new emerging biomarkers that we can now assess in the blood, as well as old, more traditional biomarkers that we're also able to assess through amyloid scans, which are positron emission tomography tests, or PET scans, as well as in the spinal tap.
So I guess what I would say overall is that there are a variety of different Alzheimer's-specific biomarkers that can now help characterize the disease better. It can also not just characterize is the person having Alzheimer's or a different neurodegenerative dementia, but also understanding a little bit more about where the person is on that long-term trajectory. For example, if there's some amyloid but there's not too much tau, or if there's amyloid and tau but not yet neurodegeneration, we can use these measures to understand really a little bit more about staging and what specific targeted therapies may be more appropriate.
At this point, I think people have questions about the differences between amyloid and tau and how they both fit in and are they equally important? Tell me your thoughts about that.
The traditional model of Alzheimer's is basically you first have the amyloid and then you have the tau, and then you have neuroinflammation, and then neurodegeneration. There's also glucose hypometabolism. So there's a variety of pathologies that one can detect in the brain on a variety of different neuroimaging studies, spinal fluid tests, as well as blood tests or plasma tests. I think we can argue all day whether amyloid causes Alzheimer's or tau causes Alzheimer's or neither causes Alzheimer's and they're just markers of the disease and the definition of what a person has in terms of their neurodegenerative dementia.
I really believe that the role of biomarkers in our field today are really twofold. Number one is to make a more accurate diagnosis and help with kind of staging of progression. The other thing I think where our field is going, and I think our field will get there in the coming years and hopefully sooner, is that we can then use these blood-based biomarkers as an example to understand are the treatments that we're giving to patients, is the lifestyle behaviors that the person is making, is the person who's controlling their blood pressure and cholesterol and blood sugar versus not, are those people having different trajectories in terms of increasing amyloid or increasing tau or changes in neurodegeneration markers and shrinkage of the brain.
So I think what the field of Alzheimer's biomarkers is now is evolving quite rapidly. And whether you just do a spinal tap to look for amyloid and tau and look at the triplicate signature of different types of tau and amyloid, or you look at the blood plasma test, which there’s only a few available currently in the United States amyloid-beta 42/40 ratio, as well as p-tau231 assessment is coming out soon, as well as other isoforms, including p-tau217 and p-tau181, and NfL [Neurofilament light chain] and GFAP [glial fibrillary acidic protein], which hopefully will be out in the coming years, or even sooner. Or even just doing an old-school FDG PET scan where you look at glucose metabolism. And if you have reduced glucose metabolism in areas of the brain that are kind of consistent with Alzheimer's disease that's another way to detect.
Basically, I think a lot of people look at Alzheimer's, as a homogeneous disease. But I really think that as we assess these biomarkers and track people long term over time, we’ll understand that Alzheimer's is actually more of a heterogeneous disease, and different people may take different roads along that track.
Marc, what do you think about that?
I think this is a key takeaway, that we're gaining so much more information about what's going on in the brain. And then we really begin to appreciate, as you said, the variability in both clinical presentation and course. And that's essential in terms of knowing what we communicate to patients in terms of what's going on and what to do.
Well, this has been a great micro discussion. Unfortunately, time is up. Everyone, thank you for listening.
You have been listening to CME on ReachMD. This activity is provided by Prova Education and is part of our MinuteCME curriculum.
To receive your free CME credit, or to download this activity, go to ReachMD.com/Prova. Thank you for listening.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Marc E. Agronin, MD
Senior Vice President, Behavioral Health
Chief Medical Officer, MIND Institute
Miami Jewish Health
Consulting Fees: Eli Lilly and Company, Otsuka America Pharmaceuticals Inc.
Contracted Research: AgeneBio, Alzheon, Inc, Avanir Pharmaceuticals, Inc, Eli Lilly and Company, F. Hoffman La-Roche Ltd, Janssen Global Services, LLC, Sage Therapeutics, Inc.
Richard S. Isaacson, MD
Director, Center for Brain Health
Florida Atlantic University
Boca Raton, FL
No relevant relationships reported.
- Cindy Davidson has nothing to disclose.
- Amanda Hilferty has nothing to disclose.
- Nick Lombardi has ownership interest in Vertex Pharmaceuticals.
- Libby Lurwick has nothing to disclose.
- Colleen Resnick has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Contrast how the slowing of Aβ plaques, as shown in recent clinical trial endpoints of slowing cognitive decline with immunotherapies, differs from current standard of care results in Alzheimer’s disease (AD)
- Recognize the positive impacts of earlier identification of AD in slowing the course of the disease
- Analyze how the mechanisms of action of newer investigational therapies relate to the molecular mechanisms that drive AD progression
- Analyze biomarkers for functional impairment, neuronal loss, and protein deposition that are assessable by neuroimaging or cerebrospinal fluid analysis for diagnosis, staging, and treatment outcomes
- Compare the monoclonal antibodies currently under study to treat AD
- Evaluate new agents that may be appropriate for patients with mild cognitive impairment (ie, the role of imaging)
This activity is designed to meet the educational needs of neurologists, primary care physicians, and other healthcare professionals that diagnose and treat patients with Alzheimer’s Disease.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.